2a:I[46696,["/_next/static/chunks/a945bbd300834012.js","/_next/static/chunks/4060b63f78e0382c.js","/_next/static/chunks/65c5d5dcc87c22c9.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/653d605fffff2e75.js","/_next/static/chunks/fa59d51a8b0726c5.js","/_next/static/chunks/a33d1a413064ef53.js","/_next/static/chunks/381ae72bfa6637bb.js","/_next/static/chunks/022589ef34b8ee03.js","/_next/static/chunks/efa6f06dc5162244.js"],"Toaster"] 2b:I[22016,["/_next/static/chunks/a945bbd300834012.js","/_next/static/chunks/4060b63f78e0382c.js","/_next/static/chunks/65c5d5dcc87c22c9.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/653d605fffff2e75.js","/_next/static/chunks/fa59d51a8b0726c5.js","/_next/static/chunks/a33d1a413064ef53.js","/_next/static/chunks/381ae72bfa6637bb.js","/_next/static/chunks/022589ef34b8ee03.js","/_next/static/chunks/efa6f06dc5162244.js"],""] 2c:I[5500,["/_next/static/chunks/a945bbd300834012.js","/_next/static/chunks/4060b63f78e0382c.js","/_next/static/chunks/65c5d5dcc87c22c9.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/653d605fffff2e75.js","/_next/static/chunks/fa59d51a8b0726c5.js","/_next/static/chunks/a33d1a413064ef53.js","/_next/static/chunks/381ae72bfa6637bb.js","/_next/static/chunks/022589ef34b8ee03.js","/_next/static/chunks/efa6f06dc5162244.js"],"Image"] 2d:I[58016,["/_next/static/chunks/a945bbd300834012.js","/_next/static/chunks/4060b63f78e0382c.js","/_next/static/chunks/65c5d5dcc87c22c9.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/653d605fffff2e75.js","/_next/static/chunks/fa59d51a8b0726c5.js","/_next/static/chunks/a33d1a413064ef53.js","/_next/static/chunks/381ae72bfa6637bb.js","/_next/static/chunks/022589ef34b8ee03.js","/_next/static/chunks/efa6f06dc5162244.js"],"ProcessEpisodeButton"] 2e:T500,

In this episode of The Rob and Jai Show from OIS XIV, hosts Dr. Rob Rothman and Dr. Jai Parekh talk with Eric Schlumpf, CEO of Stuart Therapeutics, about the company’s transformative approach to ophthalmic diseases. Learn how Stuart's innovative polypeptide technology repairs damaged collagen, advancing from dry eye to neuroprotection in glaucoma and beyond. Eric highlights key milestones, including promising clinical trial results, strategic partnerships, and the company’s plans to tackle major unmet needs like myopia and inherited retinal diseases.

In this episode, you’ll learn:

How Stuart Therapeutics’ polypeptide platform is revolutionizing ophthalmic treatments.
The potential for neuroprotection in glaucoma and what makes Stuart’s approach unique.
Why Stuart’s dry eye clinical program could be a market differentiator.
The exciting data supporting new indications like myopia and inherited retinal disease.
How strategic partnerships are fueling innovation in a capital-efficient way.

Tune in for an engaging conversation on the cutting edge of ophthalmic innovation, and find out why Stuart Therapeutics is one of the hottest companies to watch in ophthalmology.

Redefining Ophthalmic Innovation: Stuart Therapeutics’ Journey Beyond Dry Eye

Powered by Wave AI